Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in Non-cirrhotic NASH with Liver Fibrosis (REGENERATE)
NCT02548351Phase 3Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Sep 2023
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of obeticholic acid in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Intercept Pharmaceuticals. Primary endpoint: Time to the First Adjudicated Event for Clinical Outcome Composite Endpoint at 7 years. Started Sep 2015; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02548351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548351.